Vitamin D in women with polycystic ovary syndrome

INTERVENTION: All women with PCOS who fullfiled the criteria and agreed to participate in the study will be randomized (by computer‐generated randomization) into two groups. Group 1 will be treated with Vitamin D 50000 units once orally for the first week followed by 1000 units orally daily for three months starting from the first day of a spontaneous cycle or progestin withdrawal and 100 mg clomiphene citrate daily orally for five days from day three of the menstrual period. Group 2 will be treated with placebo once orally in the first week followed by placebo daily orally for three months starting from the first day of a spontaneous cycle or progestin withdrawal and 100 mg clomiphene citrate daily orally for five days from day three of menses. Ovulation is confirmed by midluteal serum P values of > 8.0 ng / ml. CONDITION: Vitamin D in women with polycystic ovary syndrome PRIMARY OUTCOME: Ovulation rate as determined by day 21 progesterone SECONDARY OUTCOME: Determination of Vitamin D, metabolic, hormonal, inflammatory and endothelial markers, and insulin resistance in women with PCOS after treatment with Vitamin D and clomiphene citrate or clomiphene citrate and placebo INCLUSION CRITERIA: Women attending the infertility clinics at King Abdulaziz University Hospital. PCOS is being defined as any women with two out of three criteria 1). Oligo‐ or anovulation; 2). Clinical and/or biochemical signs of hyperandrogenism; and 3). Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen‐secreting tumors, and Cushing's syndrome)